Clementia Pharmaceuticals are now enrolling participants in Australia for the second stage of their phase II trial of palovarotene!
An Open-Label Extension Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects is currently open for enrolments at the Queensland University of Technology. This stage will follow the 40 participants from the first stage, and enrol 20 new participants internationally in this 24 month study.
Top line results from the first stage are detailed here.
This study is only for patients who have finished growing, so this excludes most children under 15. Full trial details including inclusion criteria are available on clinicaltrials.gov (study code NCT02279095).
If you have FOP, please discuss with your health care team regarding whether you may be eligible for this trial, and whether this trial is right for you.
This is the first time part of a clinical trial has been open in Australia and a major milestone for the Australian FOP community. Although many of our community, including children and those with variant forms of FOP, will not be eligible for this trial, it is a big step forward and a cause for hope.
We are extremely grateful to the team at Clementia Pharmaceuticals (pictured above), the team at QUT, and dedicated community members who have worked together to make this happen.